C4 Therapeutics (NASDAQ:CCCC) Research Coverage Started at Stephens

Stephens assumed coverage on shares of C4 Therapeutics (NASDAQ:CCCC) in a report released on Monday morning, MarketBeat.com reports. The firm issued an equal weight rating and a $4.00 target price on the stock.

Separately, BMO Capital Markets reissued an “outperform” rating and set a $20.00 price target on shares of C4 Therapeutics in a research report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

C4 Therapeutics Stock Performance

Shares of CCCC opened at $4.05 on Monday. C4 Therapeutics has a twelve month low of $1.06 and a twelve month high of $11.88. The firm’s 50 day moving average price is $5.77 and its two-hundred day moving average price is $5.68. The firm has a market cap of $285.89 million, a P/E ratio of -2.38 and a beta of 3.04.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. The business had revenue of $15.36 million for the quarter, compared to analyst estimates of $5.95 million. On average, sell-side analysts anticipate that C4 Therapeutics will post -1.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CCCC. Headlands Technologies LLC acquired a new stake in C4 Therapeutics during the 2nd quarter worth about $45,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of C4 Therapeutics in the second quarter worth approximately $51,000. Point72 DIFC Ltd acquired a new position in C4 Therapeutics in the 3rd quarter valued at $51,000. Cynosure Group LLC purchased a new position in C4 Therapeutics in the 3rd quarter valued at $57,000. Finally, Aigen Investment Management LP acquired a new stake in C4 Therapeutics during the 3rd quarter worth $82,000. Institutional investors own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.